Loading clinical trials...

A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

A Pilot Clinical Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive Based on Imaging and Patient Reported Outcomes

NCT06095531•RevBio

View on ClinicalTrials.gov

Summary

This clinical pilot study will evaluate the use of a bioresorbable bone adhesive to improve cranial flap fixation at two study time points (at the time of fixation and 6 months). The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite for Cranial Flap Fixation (TN-CFF) to allow clinical study of the TN-CFF device in a greater number of patients.

Detailed Description

The primary endpoint is safety during the post procedure follow up period. This endpoint will be evaluated through the rate of all serious adverse device and procedure related effects from the time of fixation to 6 months post-procedure. The secondary endpoints include efficacy evaluated through radiolucency data using CT imaging at the cranial flap cut lines and the change of radiolucency with respect to time, device related adverse events, flap immobility at time of fixation, six months and 12 months, evaluation of flap translation and patient reported outcome measures.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
•Subjects can be any gender, but be between (and including) 18 and 75 years of age
•Subject is scheduled for a cranial procedure in the supratentorial location.
•Subject requires a procedure involving a Class I/clean wound (uninfected surgical wound in which no inflammation was encountered).
•Subject, and/or subject's family are able and willing to provide informed consent and HIPAA authorization.
•Subject is able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests.
•Width of craniotomy kerf line \< 3mm for more than 75% of the bone flap border

Exclusion Criteria

•Subject requires a procedure involving a translabyrinthine, transsphenoidal, transoral approach, or any procedure that penetrates the air sinus or mastoid air cells. Note: Superficial penetration of mastoid air cells is not an exclusion if cells were appropriately sealed (e.g., bone wax).
•Subject has clinically significant hydrocephalus or clinical evidence of altered CSF dynamics.
•Subject has undergone a previous, open intracranial neurosurgical procedure in the same anatomical location. (Note: stereotactic biopsy was not exclusionary).
•Subject requires a craniectomy (the bone flap is not replaced during the current surgery).
•Subject had radiation treatment to the surgical site, or standard fractionated radiation therapy was planned post index-procedure. (Note: stereotactic radiosurgery prior to the planned index procedure was not an exclusion criterion.)
•Subject has a condition with anticipated survival shorter than six months.
•Subject has undergone chemotherapy treatment, excluding hormonal therapy, within three weeks prior to the planned index procedure, or use of intracavitary chemotherapy wafer (BCNU) was planned, or chemotherapy treatment was planned within two weeks after the index procedure was performed.
•Standard use of peri-operative steroids (i.e., corticosteroids) is permitted. Chronic steroid use (defined as daily use of corticosteroids for ≥ 8 weeks) for the purposes of reducing the side effects of chemotherapy and/or radiation therapy for cancer is not exclusionary unless the patient is deemed by the investigator to be suffering from steroid toxicity (i.e., Cushing's syndrome) manifested by symptoms and signs such as thin skin, striae, easy bruising, muscle atrophy, upper body obesity, severe fatigue, etc. Use of corticosteroids on a chronic basis (as defined previously) for purposes other than decreasing the symptoms of systemic chemotherapy is exclusionary unless those steroids were discontinued 4 weeks prior to the planned index procedure.
•Subject receives warfarin, heparin, other anticoagulant agents on a daily basis and pre-surgical, standard of care drug wash-out did not occur.
•Subject is pregnant, breast-feeding, or intended to become pregnant during the course of the study.

Locations (2)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Semmes Murphey Clinic

Memphis, Tennessee, United States

Key Dates

Start Date

April 18, 2024

Primary Completion Date

December 8, 2025

Completion Date

June 30, 2026

Last Updated

February 4, 2026

Enrollment

ESTIMATED participants

Conditions

Craniotomy

Interventions

Tetranite for Cranial Flap Fixation (TN-CFF)

DEVICE

Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy

NCT07209345

Post-craniotomyPain

View study

RECRUITINGNA

A Pilot Clinical Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

NCT06780852

Craniotomy

View study

ENROLLING_BY_INVITATION

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

Inclusion Criteria

Exclusion Criteria

Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy

A Pilot Clinical Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

Effectiveness of 3D Bone Matrix in Cranioplasty

Safety and Effectiveness of TETRANITE Bone Adhesive for Cranial Flap Fixation Compared to Traditional Metal Hardware

Comparison of Post-Craniotomy Blood Pressure Targets

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block vs Bupivacaine Alone for Hemodynamics Stability in Craniotomy